Patient description: The patient is a 24-year-old man who has had type 1 diabetes for 11 years. He presents to the emergency room with hyperglycemia and concern for possible diabetic ketoacidosis after not taking his insulin for 3 days. The patient reports that he is currently homeless and has lost his supply of insulin, syringes, glucometer, and glucose testing supplies. The patient states that at the time of his initial diagnosis with type 1 diabetes he was hospitalized with a glucose value >1000 mg/dL. At the time, he was experiencing polyuria, polydipsia, and polyphagia. He reports that he has been on insulin since the time of his diagnosis, and he has never been prescribed oral agents for diabetes management. Most recently, he has been using insulin glargine 55 units once daily, and insulin aspart sliding scale 3 times daily. The patient has had previous episodes of diabetic ketoacidosis, for which he was hospitalized. With this episode of hyperglycemia, he is not experiencing any nausea, vomiting, or abdominal discomfort, and he appears well. His lab studies showed: A1c: 11.3% Creatinine: 0.9 mg/dL with eGFR >60 mL/min Aspartate aminotransferase (AST): 17 U/L Alanine aminotransferase (ALT): 14 U/L Beta-hydroxybutyrate: 0.1 mmol/L Bicarbonate: 25 mEq/L Anion

Clinical trial eligibility criteria: eligible ages (years): 18.0-75.0,  Diabetes Mellitus, Type 2 Subject states that he/she has type 2 diabetes (as evidenced by use of oral hypoglycemic medication for at least two months). 2. Subject is between 18 and 75 years of age, inclusive. 3. Subject is a male or a non-pregnant, non-lactating female, at least 6 weeks postpartum prior to screening visit. 4. If female is of childbearing potential, is practicing a method of birth control. 5. Subject's BMI is > 18.5 kg/m2 and < 35 kg/m2. 6. If on a chronic medication such as anti-hypertensive, lipid-lowering, thyroid medication or hormone therapy, subject has been on constant dosage for at least two months prior to screening visit  Subject uses exogenous insulin for glucose control. 2. Subject states that he/she has type 1 diabetes. 3. Subject states that he/she has a history of diabetic ketoacidosis. 4. Subject takes an alpha-glucosidase inhibitor. 5. Subject states that he/she has a current infection ; has had inpatient surgery, or corticosteroid treatment in the last 3 months or antibiotics in the last 3 weeks prior to screening visit. 6. Subject states that he/she has an active malignancy (excluding the following dermal malignancies: basal cell carcinoma, squamous cell carcinoma, carcinoma in-situ of the cervix). 7. Subject states that he/she has had a significant cardiovascular event ≤ six months prior to screening visit; or stated history of congestive heart failure. 8. Subject states that he/she has end stage organ failure or is status post organ transplant. 9. Subject states that he/she has a history of renal disease. 10. Subject states that he/she has current hepatic disease. 11. Subject states that he/she has a history of severe gastroparesis. 12. Subject states that he/she has a chronic, contagious, infectious disease, such as active tuberculosis, Hepatitis B or C, or HIV. 13. Subject has taken/is currently taking any herbals, dietary supplements, or medications, other than oral hypoglycemic medications, during the past four weeks prior to screening visit that could profoundly affect blood glucose. 14. Subject states that he/she has clotting or bleeding disorders. 15. Subject is known to be allergic or intolerant to any ingredient found in the study products